Wall Street is positive on Corcept Therapeutics Incorporated (CORT). On average, analysts give CORT a Buy rating. The average price target is $24.75, which means analysts expect the stock to add by 43.06% over the next twelve months.
That average ranking earns CORT an Analyst Rating of 20, which is better than 20% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
A company’s financial statements are a significant factor weighted by experts when analyzing a company’s health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What’s Happening With Corcept Therapeutics Incorporated Stock Today?
Corcept Therapeutics Incorporated (CORT) stock is trading at $17.30 as of 2:49 PM on Thursday, Dec 9, a decline of -$0.93, or -5.1% from the previous closing price of $18.23. The stock has traded between $17.26 and $19.00 so far today. Volume today is above average. So far 3,310,072 shares have traded compared to average volume of 1,423,234 shares.
Click Here to get the full Stock Report for Corcept Therapeutics Incorporated stock.
Read More: Corcept Therapeutics Incorporated (CORT) Stock: Do Analysts Think You Should Hold?